• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

QJM . Short and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes

tetano

Editor, Senior Moderator
QJM


. 2022 Jan 30;hcac020.
doi: 10.1093/qjmed/hcac020. Online ahead of print.
Short and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes


Kegang Zhan[SUP] 1 2 [/SUP], Xiaohua Zhang[SUP] 3 [/SUP], Bin Wang[SUP] 4 [/SUP], Zheng Jiang[SUP] 5 [/SUP], Xiaoyu Fang[SUP] 1 2 [/SUP], Sha Yang[SUP] 6 [/SUP], Hong Jia[SUP] 1 [/SUP], Li Li[SUP] 7 [/SUP], Guoqiang Cao[SUP] 7 [/SUP], Kejun Zhang[SUP] 8 [/SUP], Xiangyu Ma[SUP] 2 [/SUP]



Affiliations

Abstract

Background and aim: To systematically evaluate the associations between glycemic control and short- to long-term outcomes in coronavirus disease 2019 (COVID-19) patients with type 2 diabetes (T2D).
Design and methods: A multi-center prospective cohort study including 574 COVID-19 patients with T2D were conducted in Wuhan, China. All patients were followed-up 1 year after hospital discharge using a uniformed questionnaire including self-reported symptoms, and the chronic obstructive pulmonary disease (COPD) assessment test (CAT) items.
Results: Of the 574 patients, 443 (77.2%) had well-controlled blood glucose. Glycemic control was significantly associated with decreased risk of death (OR: 0.24, 95% CI: 0.10-0.57), ICU admission (OR: 0.22, 95% CI: 0.10-0.49), invasive mechanical ventilation (OR: 0.25, 95% CI: 0.08-0.72), disease progression (OR: 0.25, 95% CI: 0.11-0.55), and composite outcome (OR: 0.26, 95% CI: 0.14-0.49). The top five long-term sequelae include fatigue (31.5%), sweating (21.2%), chest tightness (15.1%), anxiety (12.2%), myalgia (10.6%), and short breath (6.4%). Glycemic control was associated with decreased risk of respiratory sequelae (OR: 0.42, 95% CI: 0.18-0.99, P = 0.048).
Conclusions: Glycemic control was significantly associated with short-term outcomes in COVID-19 patients with T2D, and showed a significant association with long-term respiratory sequelae. The management and control of blood glucose has a positive impact on prognosis of COVID-19.

Keywords: COVID-19; glycemic control; long-term; prognosis; type 2 diabetes.
 
Back
Top Bottom